Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Market Cap$3.17B
Close$
$81.95
51.1% downside
Current Fair Value
51.1% downsideOvervalued by 51.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.17 Billion |
|---|---|
| Enterprise Value | $2.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.22 |
| Beta | 0.74 |
| Outstanding Shares | 19,259,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -41.05 |
|---|---|
| PEG | 37.55 |
| Price to Sales | 18.64 |
| Price to Book Ratio | 3.9 |
| Enterprise Value to Revenue | 15.64 |
| Enterprise Value to EBIT | -88.96 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins